Roquette Takes Its Scaling Pitch to CPHI China 2026

Roquette is bringing its drug delivery portfolio to CPHI & PMEC China 2026, betting that a single supplier for excipients, capsules and formulation tech can solve a problem the industry keeps bumping into: how to scale a complex therapy without losing stability or speed.

The plant-based ingredients giant will exhibit at booth E3D26 from June 16-18 at the Shanghai New International Expo Centre. The pitch, under the tagline “One Roquette for Innovations,” is that a supplier covering all three steps reduces the handoff risk that kills projects between lab and production.

Angela Strzelecki, Senior Vice President of the Roquette Group and CEO of its Health & Pharma Solutions unit, framed the challenge in terms of manufacturing reliability. “The pressure to deliver manufacturing reliability, consistent supply, and robust formulations at scale has never been greater,” she said. She pointed to GLP-1 therapies and complex biologics as the classes where the bottleneck is sharpest.

Roquette’s PEARLITOL mannitol, manufactured in China, is the centerpiece. The excipient is designed to simplify formulation development while holding performance at commercial batch sizes. For a contract development organization or a mid-tier pharma firm trying to move a GLP-1 candidate from clinical to commercial, that matters more than the excipient chemistry itself. The risk is not whether the molecule works. It is whether the formulation can survive a 10x scale-up without a phase change or a particle-size drift that forces a revalidation cycle.

Why the Local Manufacturing Plant Matters